The government gazetted the new status on July 24, 2026, marking a significant step in the development of specialised infectious disease services, research and training in the country.
The test could also help clinicians identify patients who are unlikely to benefit from immunotherapy before treatment begins, potentially allowing them to consider alternative therapies sooner.
The expanded role is expected to strengthen referral services across Western Kenya and the wider East African region while reducing pressure on national referral hospitals.
The survey will involve about 10,000 pregnant women across all 10 regions of Cameroon.
Amylyx developed the education initiative after researching the PBH patient community.
The findings will inform a continental report intended to support evidence-based policymaking, strengthen accountability and accelerate efforts to prevent maternal and newborn deaths across Africa.
The initiative comes as scientists intensify efforts to address a major Bundibugyo ebolavirus outbreak, with cases rising rapidly in the Democratic Republic of the Congo (DRC).
Throughout the 42-day period, health authorities maintained enhanced nationwide surveillance and found no evidence of further transmission.
Leishmaniasis is endemic in 80 countries, with an estimated 50,000 to 90,000 new cases reported annually, although WHO estimates that only 25% to 45% of infections are officially documented.
Under the proposed PPP structure, the Egyptian-Turkish consortium will oversee the project’s construction and non-medical operations.